|
WO2019126776A1
|
|
Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof
|
|
WO2017192931A1
|
|
SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
|
|
EP3452480A1
|
|
Substituted pyrrolo[1,2- ]triazines and related compounds and their use in the treatment of medical disorders
|
|
WO2017192930A1
|
|
SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
|
|
WO2017192841A1
|
|
Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
|
|
CA3020305A1
|
|
Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
EP3440080A1
|
|
Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
WO2017176962A1
|
|
Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
EP3429590A1
|
|
Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject
|
|
US2019092789A1
|
|
Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders
|
|
US2019112316A1
|
|
Thiazolo[3,2-a] pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy
|
|
WO2016210116A1
|
|
Methods and compositions for treating lysosomal storage disorders
|
|
US2018369211A1
|
|
Methods and compositions for treating neurodegenerative disorders
|
|
WO2016073891A1
|
|
Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
|
|
KR20170082577A
|
|
Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
|
|
WO2016073889A1
|
|
Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
|
